Brokerages expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to post earnings per share of ($0.24) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Dicerna Pharmaceuticals’ earnings. The highest EPS estimate is ($0.13) and the lowest is ($0.28). Dicerna Pharmaceuticals posted earnings per share of ($0.92) during the same quarter last year, which indicates a positive year-over-year growth rate of 73.9%. The company is scheduled to report its next earnings report on Thursday, November 1st.
Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Dicerna Pharmaceuticals.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). The business had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.79 million. Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%.
A number of equities analysts have recently commented on the stock. SunTrust Banks lifted their target price on shares of Dicerna Pharmaceuticals to $20.00 and gave the company a “buy” rating in a report on Thursday. HC Wainwright reaffirmed a “hold” rating and issued a $14.00 target price on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 15th. Stifel Nicolaus lifted their price objective on shares of Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 9th. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 18th. Finally, ValuEngine lowered shares of Dicerna Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $15.54.
Shares of Dicerna Pharmaceuticals stock traded down $2.64 during trading on Friday, reaching $13.26. The company’s stock had a trading volume of 48,371 shares, compared to its average volume of 314,956. The stock has a market capitalization of $839.25 million, a price-to-earnings ratio of -3.93 and a beta of 2.43. Dicerna Pharmaceuticals has a fifty-two week low of $3.15 and a fifty-two week high of $17.50. The company has a debt-to-equity ratio of 0.14, a current ratio of 5.40 and a quick ratio of 5.40.
In related news, Director Dennis Langer sold 14,531 shares of Dicerna Pharmaceuticals stock in a transaction on Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total value of $232,496.00. Following the transaction, the director now directly owns 29,064 shares in the company, valued at approximately $465,024. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 19.85% of the company’s stock.
A number of large investors have recently bought and sold shares of DRNA. Millennium Management LLC grew its position in Dicerna Pharmaceuticals by 142.8% in the 4th quarter. Millennium Management LLC now owns 66,907 shares of the biopharmaceutical company’s stock valued at $604,000 after buying an additional 39,348 shares during the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth $113,000. Manchester Capital Management LLC purchased a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth $180,000. Northern Trust Corp boosted its position in shares of Dicerna Pharmaceuticals by 63.7% during the 1st quarter. Northern Trust Corp now owns 59,384 shares of the biopharmaceutical company’s stock worth $568,000 after purchasing an additional 23,102 shares in the last quarter. Finally, BlackRock Inc. boosted its position in shares of Dicerna Pharmaceuticals by 136.5% during the 1st quarter. BlackRock Inc. now owns 277,493 shares of the biopharmaceutical company’s stock worth $2,652,000 after purchasing an additional 160,172 shares in the last quarter. Hedge funds and other institutional investors own 87.02% of the company’s stock.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Featured Article: Asset Allocation and Your Retirement
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.